ArticleDrug testing and analysis2026
Identification and Structural Elucidation of a New Synthetic Cannabinoid, MDMB-5'Br-PINACA, in Seized Herbal Materials.
Article in Drug testing and analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Physicochemical Characterization and Metabolites Identification of the Synthetic Cannabinoid MDMB-5'Br-PINACA UsingChemical research in toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Synthetic cannabinoids (SCs) remain the most frequently detected class of new psychoactive substances (NPS) worldwide. Despite a recent decline in the overall number of newly reported NPS, SCs continue to emerge with remarkable structural diversity. Here, we report the discovery and structural elucidation of MDMB-5'Br-PINACA, a previously unreported SC identified in three seized herbal materials. The compound was isolated by semipreparative liquid chromatography and subsequently characterized using an integrated analytical approach combining gas chromatography-mass spectrometry (GC-MS), liquid chromatography-high-resolution mass spectrometry (LC-HRMS), and nuclear magnetic resonance (NMR) spectroscopy. In addition to MDMB-5'Br-PINACA, other SCs were detected in the analyzed materials, such as 5F-ADB and MDMB-4en-PINACA, also including the synthetic precursor MDMB-INACA. Other NPS classes were also observed, including designer benzodiazepines (N-desalkylgidazepam and bromazolam), and synthetic opioids (metonitazene). Recent years have also seen the emergence of brominated SCs as a strategy to evade legislative control, with several 5-bromo analogs detected across different regions. This analytical workflow enabled the unambiguous identification of MDMB-5'Br-PINACA and provided a detailed chemical profile of the seized samples, highlighting the continued evolution and complexity of NPS mixtures in herbal formulations. The findings emphasize the importance of continuous monitoring and early detection of emerging substances, which are essential not only for forensic and toxicological investigations but also for public health surveillance and the development of evidence-based drug control and harm-reduction policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.